Lenvatinib/Pembrolizumab Upholds Efficacy Vs Sunitinib in Frontline Advanced RCC Vs Sunitinib
After approximately 33 months of extended follow-up in the CLEAR study, investigators say lenvatinib plus pembrolizumab should be considered a standard of care option for frontline advanced renal cell carcinoma.
Need for Subsequent Therapy Limited With Lenvatinib/Pembrolizumab in Advanced RCC
Subsequent therapy rates were lower in patients with advanced renal cell carcinoma treated with the combination of lenvatinib and pembrolizumab vs those who received sunitinib in the CLEAR trial.
LenCabo Study Investigates Lenvatinib and Everolimus Vs Cabozantinib in mRCC
The newly launched phase 2 LenCabo study of lenvatinib with everolimus vs cabozantinib for the second- or third-line treatment of metastatic renal cell carcinoma.
Nivolumab Plus Ipilimumab Prolongs Survival in Treatment-Naïve Advanced Sarcomatoid RCC
Post hoc CheckMate 214 results show that nivolumab plus ipilimumab extend progression and overall survival in patient with advanced sarcomatoid renal cell carcinoma who have not be previously treated.
Doctors Debate: Should Upfront Therapy for RCC Consist of Doublets or Triplets?
During a debate at the 2022 International Kidney Cancer Symposium, Yousef Zakharia, MD and Rana M. McKay, MD presented argument for the use of doublets or triplets in patients with renal cell carcinoma.canc
Promising Results of Cabozantinib/Nivolumab in Non-Clear Cell RCC Could Guide Future Research
In an interview with Targeted Oncology, Chung-Han Lee, MD, PhD further discussed the results of the phase 2 trial of the combination of cabozantinib and nivolumab in patients with metastatic non-clear cell RCC and how it impacts the future of this space.
Immune Checkpoint Inhibitors Encouraging for Perioperative RCC Treatment
In an interview with Targeted Oncology™, Naomi B. Haas, MD, discussed how the research has pivoted toward exploring neoadjuvant treatment for patients with renal cell carcinoma.
Research Explores Possible Link Between Gut Microbiome and Better Outcomes in Kidney Cancer
In an interview with Targeted Oncology, Nazli Dizman, MD, discussed the role of gut microbiome in cancer and speaks to her presentation given at IKCS.
Post-Hoc Analysis Shows Adverse Events With First-line Nivolumab Plus Cabozantinib Are Manageable
In a post-hoc analysis of the CheckMate 9ER trial, researchers found that, along with additional efficacy benefits, the combination of nivolumab plus cabozantinib had manageable adverse events.
Viability of Cytoreductive Nephrectomy Followed by Active Surveillance in mRCC Upheld
Compared with systemic therapy administered after cytoreductive nephrectomy, active surveillance was an option for some patients with metastatic renal cell carcinoma.
With NIVO + IPI, Advanced RCC Survival Approaches 5 years
Compared with sunitinib, the combination of nivolumab an ipilimumab produced better long-term responses, with overall survival approaching 5 years.
Select Transcriptional Signatures in nccRCC May Have Clinical Potential, Research Shows
New findings suggest that understanding subtypes of non-clear cell renal cell carcinoma is important for personalizing treatment.
Metastatic RCC Survival Approaching 5 Years
James Brugarolas, MD, PhD, discusses updated survival data in patients with metastatic renal cell carcinoma.
Efficacy and Safety Assessment of Frontline Lenvatinib Plus Pembrolizumab Underway for nccRCC
The frontline combination of lenvatinib and pembrolizumab is under investigation as a treatment option for patients with non-clear cell renal cell carcinoma in the recently launched phase 2 KEYNOTE-B61 trial.
Precision Medicine According to Histologic Subtype in Renal Cell Carcinoma
During a presentation at the 2021 International Kidney Cancer Symposium, Bradley McGregor, MD, discussed analyses of outcomes based on histology in major RCC clinical trials, and how this approach will shape the future of treatment.
Potential Benefits of Lenvatinib in Renal Cell Carcinoma
Naomi B. Haas, MD, medical oncologist, discusses the potential benefits of lenvatinib for the treatment of renal cell carcinoma.
Integrating Palliative Care in Kidney Cancer
Limited data exists on the effects of palliative care in patients with kidney cancer, and more research is needed.
Expert Insights on the Evolving Treatment Paradigm During Kidney Awareness Month
In an interview with Targeted Oncology, Walter M. Stadler, MD, discussed recent updates and changes in the kidney cancer landscape, including treatment with HIF and VEGFR inhibitors.
Immunotherapy Plus TKI Regimens Appear Promising for Patients With Renal Cell Carcinoma
In an interview with Targeted Oncology, Chung-Han (Joe) Lee, MD, PhD, discussed the use of different targeted therapy and immunotherapy strategies for the treatment of patients with metastatic kidney cancer.
Lenvatinib Plus Everolimus Induces Responses in Rare RCC Population
In an interview with Targeted Oncology, Thomas E. Hutson, DO, PharmD, discussed the difficult-to-treat nccRCC patient population and the promise of lenvatinib plus everolimus, as well as other combination regimens.
Award-Winning Physicians to Present Special Lectures on Advances and Unmet Needs in the Field During IKCS 2020
At the International Kidney Cancer Symposium Virtual Event, the 2019 Nobel Laureate and recipients of the Kidney Cancer Association’s Andrew C. Noviak Award and the Pieter de Mulder Memorial Award will give lectures on key topics in the kidney cancer landscape on November 6 and 7.
2 Commerce Drive Cranbury, NJ 08512